Complete adverse effect profile including incidence rates and management
Important Safety Information
This is not a complete list of all possible side effects. Contact your healthcare provider if you experience any unexpected symptoms. For serious or life-threatening side effects, seek emergency medical attention immediately.
Diarrhea (20% in IBS-C trials; 16% in CIC trials) — the most frequently reported adverse effect, often occurring within the first few weeks of therapy
Abdominal pain (7%) — may occur or worsen transiently at treatment initiation
Flatulence (4-6%) — increased gas production due to altered intestinal transit
Abdominal distension (3-5%) — bloating sensation, particularly early in therapy
Nausea (2-4%) — generally mild and transient
Viral gastroenteritis (3%) — increased susceptibility reported in clinical trials
Dyspepsia (2%) — upper abdominal discomfort or indigestion
Headache (1-2%) — non-specific; mechanism unclear
Fecal incontinence (1-2%) — associated with loose or liquid stools
Sinusitis (2%) — upper respiratory adverse event noted in trials
Urinary tract infection (1-2%) — reported with slightly higher frequency versus placebo
Gastroesophageal reflux disease (GERD) (<2%) — possibly related to altered GI motility
Loose stools — a frequent complaint, distinct from true diarrhea by volume and urgency criteria
Severe diarrhea (Black Box Warning) — can lead to clinically significant dehydration, hypovolemia, and electrolyte imbalances, particularly dangerous in pediatric patients; discontinue immediately if severe diarrhea occurs
Dehydration — especially in vulnerable populations including elderly patients and those with baseline fluid-electrolyte imbalances; monitor hydration status
Electrolyte disturbances — hypokalemia, hyponatremia secondary to excessive fluid loss from severe diarrhea
Hypovolemia — reduced blood volume from fluid losses can precipitate hypotension and tachycardia in severe cases
Syncope or pre-syncope — reported in post-marketing experience, potentially related to dehydration and autonomic response
Intestinal obstruction — while rare, discontinuation is warranted if mechanical obstruction is suspected or confirmed as linaclotide could exacerbate symptoms
Rectal hemorrhage — uncommonly reported; evaluate for organic lower GI pathology if bleeding occurs
Ischemic colitis — rare post-marketing reports; discontinue and evaluate if sudden onset severe abdominal pain with rectal bleeding occurs
Rectal hemorrhage — uncommon but reported in post-marketing surveillance
Hematochezia — passage of fresh blood per rectum, requires clinical evaluation to rule out serious pathology
Thyroid neoplasm (benign) — noted at high doses in long-term animal carcinogenicity studies; clinical relevance in humans at therapeutic doses is not established
Allergic reactions — hypersensitivity including rash, urticaria, or angioedema, though rare given minimal systemic absorption
Ischemic colitis — rare post-marketing case reports requiring prompt evaluation
Collagenous colitis — isolated case reports in temporal association with linaclotide use
Severe hypokalemia — in patients with baseline electrolyte vulnerabilities experiencing prolonged diarrhea
Like all medications, Linzess can cause side effects. However, not everyone who takes this medication will experience them. Many side effects are dose-dependent and may improve as your body adjusts to the medication. Others may require dose adjustment or medical attention.
Contact your healthcare provider promptly if you experience:
Seek immediate emergency medical care if you experience signs of: